Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Oleo Sci ; 71(10): 1481-1492, 2022 Sep 30.
Artículo en Inglés | MEDLINE | ID: mdl-36089399

RESUMEN

Renal tissue plays a crucial function in maintaining homeostasis, making it vulnerable to xenobiotic toxicity. Pueraria montana has more beneficial potential against the various diseases and has long history used as a traditional Chinese medicine. But its effect against the renal cancer not scrutinize. The goal of this study is to see if Pueraria montana can protect rats from developing kidney tumors caused by diethylnitrosamine (DEN) and ferric nitrite (Fe-NTA). Wistar rats was selected for the current study and DEN (use as an inducer) and Fe-NTA (promoter) for induction the renal cancer. For 22 weeks, the rats were given orally Pueraria montana (12.5, 25, and 50 mg/kg) treatment. At regular intervals, the body weight and food intake were calculated. The rats were macroscopically evaluated for identification of cancer in the renal tissue. The renal tumor makers, renal parameters, antioxidant enzymes, phase I and II enzymes, inflammatory cytokines and mediators were estimated at end of the experimental study. Pueraria montana treated rats displayed the suppression of renal tumors, incidence of the tumors along with suppression of tumor percentage. Pueraria montana treated rats significantly (p < 0.001) increased body weight and suppressed the renal weight and food intake. It also reduced the level of renal tumor marker ornithine decarboxylase (ODC) and [3H] thymidine incorporation along with suppression of renal parameter such as uric acid, blood urea nitrogen (BUN), urea and creatinine. Pueraria montana treatment significantly (p < 0.001) altered the level of phase enzymes and antioxidant. Pueraria montana treatment significantly (p < 0.001) repressed the level of tumor necrosis factor-α (TNF-α), interleukin-1ß (IL-1ß), interleukin-6 (IL-6) and improved the level of interleukin-10 (IL-10). Pueraria montana treatment suppressed the level of prostaglandin (PGE2), cyclooxygenase-2 (COX-2), nuclear kappa B factor (NF-κB) and transforming growth factor beta 1 (TGF-ß1). Pueraria montana suppressed the inflammatory necrosis, size the bowman capsules in the renal histopathology. Pueraria montana exhibited the chemoprotective effect via dual mechanism such as suppression of inflammatory reaction and oxidative stress.


Asunto(s)
Neoplasias Renales , Pueraria , Animales , Antioxidantes/farmacología , Biomarcadores de Tumor/metabolismo , Biomarcadores de Tumor/farmacología , Peso Corporal , Creatinina/farmacología , Ciclooxigenasa 2/metabolismo , Dietilnitrosamina/farmacología , Compuestos Férricos , Inflamación/tratamiento farmacológico , Interleucina-10 , Interleucina-1beta/metabolismo , Interleucina-6/metabolismo , Neoplasias Renales/inducido químicamente , Neoplasias Renales/tratamiento farmacológico , Neoplasias Renales/metabolismo , FN-kappa B/metabolismo , Ácido Nitrilotriacético/análogos & derivados , Nitritos/farmacología , Ornitina Descarboxilasa/metabolismo , Ornitina Descarboxilasa/farmacología , Estrés Oxidativo , Prostaglandinas , Prostaglandinas E/metabolismo , Prostaglandinas E/farmacología , Pueraria/metabolismo , Ratas , Ratas Wistar , Timidina/metabolismo , Timidina/farmacología , Factor de Crecimiento Transformador beta1/metabolismo , Factor de Crecimiento Transformador beta1/farmacología , Factor de Necrosis Tumoral alfa/metabolismo , Urea , Ácido Úrico/farmacología , Xenobióticos/farmacología
2.
Biol Reprod ; 106(4): 792-801, 2022 04 26.
Artículo en Inglés | MEDLINE | ID: mdl-34935905

RESUMEN

In all mammalian species examined thus far, the ovaries produce a burst of ornithine decarboxylase (ODC) and putrescine during ovulation or after application of human chorionic gonadotropin (hCG). Aged mice have significantly reduced levels of this periovulatory ODC and putrescine rise. Putrescine supplementation, in vitro during oocyte maturation or in mouse drinking water during the periovulatory period, reduces egg aneuploidies and embryo resorption, improving fertility of aged mice. These studies suggest that periovulatory putrescine supplementation may be a simple and effective therapy for reproductive aging for women. However, putrescine supplementation is expected to increase widespread tissue putrescine levels, raising concerns of nonspecific and unwanted side effects. Given that ODC is highly expressed in the ovaries during ovulation but otherwise exhibits low activity in most tissues, we hypothesized that periovulatory supplementation of L-ornithine, the substrate of ODC, might be suitable for delivering putrescine specifically to the ovaries. In this study, we have demonstrated that systemic application of L-ornithine via oral gavage or subcutaneous injection increased ovarian putrescine levels; the increase was restricted to animals that had been injected with hCG. Furthermore, L-ornithine specifically increased ovarian putrescine levels without affecting putrescine levels in any other tissues. However, our attempts to improve fertility of aged mice through L-ornithine supplementation in mouse drinking water produced either no effects (1% L-ornithine) or negative impact on fertility (4% ornithine). Our results suggest that it might not be feasible to achieve fertility-enhancing ovarian putrescine levels via L-ornithine supplementation in drinking water without encountering undesired consequences of high dose of exogenous L-ornithine.


Asunto(s)
Suplementos Dietéticos , Ornitina , Putrescina , Animales , Gonadotropina Coriónica/farmacología , Agua Potable , Femenino , Humanos , Ratones , Ornitina/farmacología , Ornitina Descarboxilasa/farmacología , Ovario , Ovulación , Putrescina/farmacología
3.
Nihon Geka Gakkai Zasshi ; 99(6): 362-7, 1998 Jun.
Artículo en Japonés | MEDLINE | ID: mdl-9695073

RESUMEN

Chemoprevention of colorectal cancer has been extensively investigated in animal models and in high-risk human populations with inherited or acquired genetic changes, using anticarcinogenic agents from natural and synthetic sources. To understand active agents using a short-term assay, reliable intermediate biomarkers other than cancer are required as end-points. Endoscopically detectable aberrant crypt foci and adenomas are useful biomarkers in human intervention trials. Indomethacin and other nonsteroidal antiinflammatory drugs (NSAIDs) inhibit carcinogen-induced colon cancer development in rats. It was reported that a number of colorectal polyps in familial adenomatous polyposis patients regress after several months of sulindac treatment. Epidemiological studies have shown that regular use of aspirin and other NSAIDs reduces the risk of colorectal cancers and adenomas. In addition, ursodeoxycholic acid and alpha-difluoromethylornithine, a selective inhibitor of ornithine decarboxylase, have been employed in human intervention trials. Vegetable antioxidants such as carotenoids and flavonoids, omega-3 fatty acids, lactic acid bacteria, and indigestible oligosaccharides may also be promising chemopreventive agents.


Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Antineoplásicos/farmacología , Neoplasias Colorrectales/prevención & control , Eflornitina/farmacología , Animales , Carotenoides/farmacología , Neoplasias Colorrectales/inducido químicamente , Neoplasias Colorrectales/patología , Ácidos Grasos Omega-3/farmacología , Humanos , Ornitina Descarboxilasa/farmacología , Ratas , Ácido Ursodesoxicólico/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA